< 1 minute read
Nov. 26, 2021

AZD5305: An Oral PARP1-DNA Selective Trapper

AZD5305

oral PARP1-DNA selective trapper 1 mpk QD in PDX model, phase I/II, cancer from literature starting point Journal of Medicinal Chemistry AstraZeneca

drughunter.com
Drug Hunter Team

The AstraZeneca PARP1-DNA trapper, AZD5305 , is a phase I candidate (NCT04644068) for cancer that is selective for PARP1 over PARP2 (>500x). Their study began by profiling the existing clinical and late-stage PARP inhibitors in vitro, finding that the seven leading compounds (olaparib, rucaparib, niraparib, talazoparib, veliparib, NMS-P118 [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in